Arirang Insight.

Executive Summary

Korea is changing the order in which it pays for medicines. For years, a drug had to clear a long, front-loaded value assessment before public insurance would cover it. Under a new "reimburse first, then evaluate" approach, the country will begin paying for selected rare-disease treatments first, then verify their value afterwards using real-world data.

The shift was signalled at the top. On 2 January 2026, the president of the Health Insurance Review and Assessment Service (HIRA), Kang Joong-gu, used his New Year address to call for lower reimbursement barriers on expensive treatments for rare and serious diseases, paired with tougher checks after coverage begins. "We need to move toward a structure where we provide treatment opportunities first, then verify effectiveness and value through real-world data," he said.

For international healthcare and MedTech leaders, this is more than an administrative tweak. It changes when a company gets paid in Korea, what evidence it must keep generating after launch, and where Korea sits in a global launch queue. The reform is phased and unfinished, but the direction is now set.

What Happened

Reimbursement in Korea has long run in sequence. After the Ministry of Food and Drug Safety (MFDS), the drug regulator, approves a product, HIRA assesses its clinical and economic value, the National Health Insurance Service (NHIS) negotiates price, and the Ministry of Health and Welfare (MOHW) signs off. Each stage follows the last. The formal review clock is 240 days, but in practice some rare-disease therapies have taken more than three years to move from approval to coverage.

Kang's New Year message named the trade-off directly: rapid patient access on one side, fiscal control on the other. HIRA would lean harder on tools it already has, such as conditional coverage and risk-sharing agreements, to get patients treated sooner. In return, it would intensify monitoring of real clinical outcomes, safety and cost-effectiveness once a drug is covered. He framed it as a limit of the old model: there are limits to trying to remove all uncertainty at the moment coverage is decided.

The mechanism behind the rhetoric is concrete. Under the emerging "reimburse first, then evaluate" paradigm, rare-disease treatments would target reimbursement within 100 days. HIRA and NHIS would review in parallel rather than in sequence, sharing information in real time to cut the hand-offs that compound delay. Value assessment at listing could be streamlined, with international price benchmarks used in place of full economic modelling, and a formal price reassessment would follow after listing using real-world evidence. The government is exploring AI-enabled infrastructure to speed that review.

The timeline is staged. The approach is set to be piloted in the second half of 2026, implemented in 2027, and expanded to selected innovative medicines beyond rare diseases from 2028. That expansion matters: it turns a targeted rare-disease fix into a broader signal about how Korea intends to reward innovation.

The reset does not stand alone. It sits inside a wider 2026-2028 reform package described by market-access analysts at Simon-Kucher. A flexible contract system, implemented in June 2026, lets a drug carry a high public list price while the actual reimbursed price is negotiated confidentially with NHIS, reducing the international reference-pricing exposure that has long deterred launches. Weighted cost-effectiveness thresholds, due in 2027, would let value assessments weigh disease severity and clinical benefit rather than lean only on a low, fixed cost-per-QALY line unchanged since 2006. On the regulatory side, MFDS has said it aims to cut biosimilar review times from up to 420 days to 240, and to formalise humanitarian access to high-cost orphan drugs. The pieces point the same way: faster access, paid for by tighter post-market scrutiny.

Why It Matters

The clearest read-across is launch sequencing. Korea has often been deprioritised in global launch plans, not because the market is small but because access was slow and prices, once set low and disclosed, could drag down negotiations elsewhere. Compressing the rare-disease pathway toward 100 days, and pairing it with confidential pricing, weakens two of the reasons companies held Korea back. Manufacturers with oncology, rare-disease and neurology launches ahead should reassess where Korea belongs in their sequence, because early entrants tend to set the pricing precedents others inherit.

The reform also changes what "getting reimbursed" means. Under a reimburse-first model, coverage is no longer the finish line. It is the start of an ongoing evidence and pricing dialogue with HIRA, NHIS and MOHW, with price reassessment leaning on real-world data. That raises the value of a Korea-specific evidence strategy built into clinical development from the outset, rather than assembled after listing. Companies that treat real-world data collection as a launch afterthought will be exposed when the reassessment arrives.

There is a fiscal logic worth naming. Paying first and verifying later transfers risk onto the payer, so Korea is balancing it with sharper post-market surveillance and the ability to unwind or reprice weak performers. For the state, the bet is that faster access plus disciplined follow-up costs less than the current mix of long delays and blunt price control. For companies, it means the scrutiny does not disappear; it moves downstream.

The read-across for MedTech and diagnostics is the direction of travel. A system moving toward value assessed on outcomes, and willing to weigh severity and benefit rather than a single threshold, favours technologies that can prove downstream impact. The risk sits on pace. The pathway is still a pilot, eligibility and operational detail remain unsettled, and a reform that is announced is not yet a reform that is reliable.

Executive Summary

On 26 January 2026, South Korea's Ministry of Health and Welfare (MOHW) and Ministry of Food and Drug Safety (MFDS) launched the "Market Immediate Entry Medical Technology" system, a fast-track approval pathway that compresses regulatory timelines by 70% for innovative medical devices, particularly AI-based diagnostics and surgical robotics. The reform applies to 199 device categories and permits market entry immediately after MFDS approval, bypassing the separate New Medical Technology (NMT) assessment that previously added 6–12 months to the process.

For international MedTech companies, this represents a strategic inflection point: Korea transforms from a sequential, multi-step approval system into a competitive launch market on par with major Western jurisdictions.

What Happened

The fast-track system became effective 26 January 2026, following a pilot phase in 2025. It applies to devices that meet specific innovation criteria and pass reinforced clinical evaluation during MFDS authorization.

Timeline compression: The old pathway required approval from MFDS, followed by a separate assessment by a government-designated institute under the New Medical Technology (NMT) framework, adding 200–300 days to the process. The total time-to-clinical use could exceed 490 days. Under the new system, after MFDS approval, innovative devices enter clinical use directly within 80–140 days total.

Scope: 199 device categories are eligible: - 113 digital health devices and Software as a Medical Device (SaMD), especially AI-based algorithms for diagnostics and monitoring. - 83 in-vitro diagnostic (IVD) reagents. - Robotic devices, including surgical robots, assistive exoskeletons, and orthopedic systems.

Regulatory basis: The framework amended two key regulations—the "Regulation on the Evaluation of New Medical Technologies" (MOHW) and the "Rules on the Authorization, Notification and Review of Medical Devices" (MFDS)—establishing a new "immediate-entry medical technologies" category for devices that passed reinforced clinical evaluation.

Why It Matters

Market timing: Korea's medical device market is valued at $7.5 billion (2025) and projected to grow at 7.5% CAGR through 2032. Diagnostics and monitoring devices are the fastest-growing segment, driven by aging demographics, healthcare AI integration, and government investment in smart hospitals. The fast-track system removes friction precisely when investor and corporate interest in Korea's AI-healthcare ecosystem is highest.

Competitive positioning: Foreign companies (which account for 88.7% of tertiary hospital device units in Korea) benefit immediately. A surgical-robot or AI-diagnostic manufacturer that would previously face a 12+ month wait after MFDS approval now enters clinics in 80–140 days. This advantage is particularly valuable for companies targeting the region's well-funded hospital systems and reimbursement infrastructure.

Policy signal: The reform reflects Korea's strategic pivot toward innovation-first healthcare. The concurrent 645 million USD ($940.8 billion won) medtech R&D initiative and 30 billion won AI-deployment program in regional hospitals signal that Korea is not just welcoming foreign innovation but building the infrastructure (clinical sites, reimbursement pathways, integration standards) to absorb it at scale.

Asia-wide context: China is simultaneously implementing similarly aggressive device fast-tracks; this Korean move signals competitive urgency among Asian economies to become preferred launch platforms for MedTech startups and multinational device companies before market maturity.

Executive Summary

South Korea implemented the "Immediate Market Entry Medical Technology System" in January 2026, cutting the approval timeline for internationally validated medical devices from 490 days to as few as 80 days. The fast-track applies to AI diagnostics, surgical robots, and other innovative technologies meeting pre-defined criteria. This regulatory acceleration arrives as Korea's healthcare sector stabilizes after a prolonged strike, foreign manufacturers dominate high-end hospital segments, and the country officially entered a super-aged society. The reform signals Korea's bet on fast innovation cycles over cautious regulatory gatekeeping—reshaping which companies win in Korean hospitals.

What Happened

In January 2026, Korea's Ministry of Food and Drug Safety (MFDS) launched the "Immediate Market Entry Medical Technology System" (IME-MTS), a regulatory pathway that allows internationally validated medical devices to enter the Korean market and be deployed in clinical practice within 80 days, bypassing the standard 490-day health technology assessment (HTA) process.

The fast-track targets specific device categories: AI-powered diagnostic systems, surgical robotics, and other innovations meeting three criteria. The device must be approved by a recognized international regulator (FDA, CE mark, or equivalent). The manufacturer must commit to post-market surveillance. The device must address an unmet clinical need or demonstrate clinically meaningful innovation.

The reform arrived alongside the Digital Medical Products Act (DMPA), enacted in 2026, which established a dedicated regulatory framework for software-as-a-medical-device (SaMD) and digital therapeutics. The DMPA introduced stringent cybersecurity mandates and data-protection requirements, creating a distinct pathway for digital health innovations separate from traditional physical devices.

Korea's broader healthcare context frames this shift. The country's two-year trainee doctors' strike (February 2024–September 2025) disrupted hospital operations and deferred capital expenditure on medical equipment. As the strike resolved, hospitals accumulated replacement demand. Simultaneously, South Korea officially entered a "super-aged society" in late 2024, with over 20% of the population now aged 65 or older, driving demand for remote monitoring, continuous glucose monitoring systems, and chronic disease management technologies.

The medical device market itself reflects structural dualism. South Korea imports roughly $4.4–5.3 billion USD annually in medical devices. The United States supplies 40–50% of all imports; Germany and Japan are secondary suppliers. Domestic manufacturers dominate volume-driven segments (primary clinics, mid-tier hospitals) through aggressive pricing and responsive local service. However, tertiary hospitals—which handle complex cases and command the highest budgets—procure 88.7% foreign devices. In high-end ultrasound imaging, domestic penetration in tertiary hospitals stands at just 21.1%.

Why It Matters

The fast-track reform tilts competitive advantage toward companies with international validation and innovation pedigree. If you hold FDA or CE approval, Korea now becomes a rapid incremental market. If you lack international credentials, the traditional 490-day pathway remains your only route—a material disadvantage.

For MedTech manufacturers already serving North America or Europe, the 80-day Korean entry now makes sense in near-real-time commercial planning. AI diagnostic vendors, surgical robot makers, and digital health companies can sequence launches across North America, Europe, and Korea within a single fiscal cycle, rather than staggering entries across years. This compressed timeline favors companies with capital to sustain parallel regulatory submissions, pricing strategies, and clinical evidence packages across multiple regions.

The tertiary-hospital dominance of foreign devices creates a concentration effect. These hospitals drive innovation adoption and set clinical standards. If your device clears the fast-track and secures tertiary-hospital pilot deployments, you gain clinical reference sites and reputational momentum in a market of 60+ million. The downstream effect—adoption by mid-tier hospitals and clinics—follows more slowly but is nearly assured once the tertiary-hospital bar is met.

Korean domestic manufacturers face a genuine constraint. Few hold FDA or CE approval; most build for the domestic market first. The fast-track effectively reserves the 80-day advantage for international players, widening the timeline gap domestic makers must overcome to compete in high-end segments. Over time, this could reshape the competitive balance between foreign and domestic suppliers.

The super-aged society dynamic amplifies this. Remote monitoring, AI-powered triage, and chronic disease management technologies will see sustained demand across the next decade. The fast-track makes Korea an attractive early-stage market for companies building these platforms. Pilot deployments in Korean hospitals—especially if they include geriatric-focused institutions—generate compelling clinical data for other aging markets (Japan, Taiwan, Europe).

Regulatory risk is not eliminated. The DMPA's cybersecurity mandates are stringent; companies unfamiliar with Korean data-protection expectations should budget for compliance review. Post-market surveillance commitments are binding. However, these are known costs. The 80-day timeline is certain.

Executive Summary

Korea has removed the most expensive step in biosimilar development. On 14 July, the Ministry of Food and Drug Safety (MFDS), the country's drug and device regulator, put into force a revised rule that lets biosimilar developers win approval without submitting Phase 3 clinical trial data. The condition is that similarity to the original biologic is already proven through laboratory, non-clinical, and pharmacokinetic testing.

The change reaches the core economics of the business. Phase 3 trials enrol large numbers of patients and absorb much of the time and money in bringing a biosimilar to market. Removing that requirement, where the science supports it, compresses both. Korea also dropped a repeat-dose animal toxicity requirement on the same logic.

For international readers, this is a market-structure signal, not a technical footnote. Korea is home to two of the world's largest biosimilar makers, Celltrion and Samsung Bioepis. The reform lowers their cost of shipping product and follows parallel moves by regulators in Europe, the United States, and Canada. The direction of travel is a global standard in which analytical science, rather than large efficacy trials, becomes the basis for approving a copy of a biologic drug.

What Happened

MFDS announced on 14 July that it had revised and implemented the Regulation on the Approval and Review of Biological Products. The revision eases the data a company must submit to prove a biosimilar matches its reference product.

The old rule was strict. A developer seeking marketing approval had to submit data from both a Phase 1 trial and a Phase 3 trial to demonstrate biosimilarity. Under the revised regulation, the sponsor may omit the Phase 3 data if comparability has already been established through quality, non-clinical, and pharmacokinetic studies. Pharmacokinetic studies track how the drug moves through the body. Where those measures line up with the reference product, the confirmatory efficacy trial is no longer automatic.

The regulation also reflects the global push to reduce animal testing. Companies will no longer need to submit repeated-dose toxicity study data when comparability in product quality and pharmacological behaviour has been adequately shown.

The reform did not appear overnight. It follows an initiative announced at Korea's presidential Bio Innovation Forum in September 2025 to strengthen the biosimilar industry, and MFDS drafted the change with industry through a public-private consultative body on biosimilar clinical development. Earlier steps came in March, when the ministry published guidance on the factors that decide whether a Phase 3 trial is needed and opened a pre-submission consultation system that lets developers settle trial requirements with regulators before filing.

Industry read the move quickly. Seoul Economic Daily reported that Celltrion and Samsung Bioepis stand to benefit most, since both draw the bulk of their revenue from biosimilars and carry deep development pipelines. A Samsung Bioepis official said the company is already advancing some undisclosed follow-on programmes on the assumption of a Phase 3 exemption, having received regulator feedback that approval is possible without it, and now plans to run only Phase 1 studies for those products.

Why It Matters

The reform changes the unit economics of a biosimilar. Analytical characterisation and pharmacokinetic work are comparatively cheap and fast. A large comparative-efficacy trial is neither. By allowing the expensive step to be waived when the cheaper evidence is convincing, MFDS shortens the path from cell line to launch and cuts the capital at risk in each programme. The US Food and Drug Administration has made the same argument for its own abbreviated pathway, noting that biosimilar makers do not need to run as many long and costly clinical trials because the goal is to prove similarity, not to re-establish a drug's safety and effectiveness from scratch.

The wider point is convergence. Korea is not moving alone. In March, the European Medicines Agency's human-medicines committee adopted a reflection paper concluding that analytical comparability and pharmacokinetic data can, in defined circumstances, be enough to approve a biosimilar without a Phase 3 trial. The FDA issued a draft guidance the same month aimed at trimming unnecessary clinical pharmacokinetic testing, estimating that the change could save developers up to half of their PK-study costs, or roughly 20 million dollars per programme. Health Canada revised its own guidance in May to say comparative clinical efficacy studies are not typically required. Korea's rule slots into that emerging consensus.

For companies that file across borders, harmonisation is the prize. A biosimilar developer builds one evidence package and takes it to many regulators. When Seoul, Brussels, Washington, and Ottawa converge on what that package must contain, a streamlined dossier can serve several markets at once. That lowers duplicate spending and speeds multi-market launches, which is precisely the model Celltrion and Samsung Bioepis run.

The competitive consequences cut in more than one direction. For Korea's biosimilar leaders, cheaper and faster development means more programmes and more shots at the large wave of biologics losing patent protection over the rest of the decade. For originator companies, it means biosimilar competition may arrive sooner and at lower cost, tightening the window in which a branded biologic enjoys open-field pricing. For the contract research industry, demand shifts away from large Phase 3 comparative trials toward analytical and pharmacology work. For investors, the barrier to entry in biosimilars falls, which favours scale and manufacturing quality over the ability to finance a long trial.

None of this is a free pass. The waiver is conditional, not automatic. A developer still has to prove biosimilarity through rigorous analytics and pharmacokinetics, and the regulator keeps discretion over when a confirmatory trial is warranted. Products seeking interchangeable status, or those where the analytical picture is less clean, may still face heavier evidence demands. A lower barrier also invites more entrants, which can compress prices and margins in crowded molecules. The reform improves the odds and the economics of biosimilar development in Korea. It does not remove the science.

Executive Summary

Korea delivers among the best health outcomes in the developed world using the fewest doctors. That is the paradox at the centre of the government's latest reading of OECD data, released on 23 July 2026.

The country has the second-lowest number of practising physicians in the OECD. It also has the most hospital beds, one of the highest scanner densities, the highest outpatient-visit rate, and near the longest hospital stays. In other words, Korea substitutes capital and volume for physician labour, and it does so at a level no other member country approaches.

For international healthcare and MedTech leaders, this is not a curiosity. It explains two things at once: why Korea is a structurally strong market for anything that stretches scarce clinical staff, and why the government is now moving to squeeze the capital-heavy, high-volume segments through reimbursement reform. The same data that shows opportunity also marks the target.

What Happened

On 23 July, the Ministry of Health and Welfare (MOHW) — the government department that sets health policy and oversees the national insurance system — published its analysis of OECD Health Statistics 2026. The dataset compares 27 indicators across seven categories, from workforce and infrastructure to spending and long-term care. The figures below are as of 2024.

The workforce numbers are the outlier. Korea had 2.6 practising physicians per 1,000 people, including doctors of traditional Korean medicine. The OECD average is 4.0, and only Costa Rica ranked lower. The pipeline is thin too: 7.3 medical graduates per 100,000 people, less than half the OECD average of 15.3. Registered nurses stood at 5.5 per 1,000, well below the average of 8.8.

Set against that scarcity, the infrastructure figures invert. Korea had 12.5 hospital beds per 1,000 people, nearly three times the OECD average of 4.2 and the highest in the group. It had 39.3 MRI units and 46.7 CT scanners per million people, both above OECD averages of 21.5 and 31.5. The average Korean visited a doctor 17.9 times in the year, about 2.7 times the OECD average of 6.6 and the highest of any member. The average hospital stay ran to 17.9 days, second only to Japan.

Utilisation follows the equipment. Korea recorded 338.7 CT examinations per 1,000 people, roughly double the OECD average and the highest anywhere. One detail matters for vendors: MRI use, at 83.2 per 1,000, actually sits below the OECD average, and it is growing faster than CT — 10.8 percent a year over the past decade against CT's 7.5 percent.

Spending is climbing. Current health expenditure was 8.5 percent of GDP, still below the OECD average of 9.3 percent. But per-capita spending reached $5,098.7 in purchasing-power-parity terms and grew at 8.5 percent a year over the decade, well ahead of the 6.1 percent OECD pace. Per-capita pharmaceutical sales, at $1,041.2, ran about 47 percent above the OECD average. The outcomes bought with all this are genuinely strong: life expectancy of 83.7 years, second only to Switzerland, and avoidable mortality a third below the OECD average.

The comparison with last year's release sharpens the trend. In the 2025 data, Korea had 2.7 physicians per 1,000 and per-capita spending of $4,586. In one year, the doctor ratio edged down and spending rose more than $500. The direction is consistent: fewer clinicians, more throughput, higher cost.

Why It Matters

The strategic reading runs in two directions at the same time, and executives need to hold both.

Doctor scarcity is a durable demand signal. Korea cannot expand its physician base quickly. Medical training takes a decade, the graduate rate is less than half the OECD norm, and the attempt to raise medical-school admissions triggered the prolonged trainee-doctor walkout of 2024 and 2025. That constraint is structural, not budgetary, which makes demand for anything that stretches clinical time unusually resilient. Imaging AI that helps a thin radiology workforce read a rising scan volume, decision-support tools, laboratory automation, and remote monitoring all sell into a genuine shortage rather than a discretionary preference. This is the same logic behind Korea's recent move to relax the full-time-radiologist rule for MRI sites and its state funding for AI-specialised hospitals: the system is looking for ways to do more with fewer doctors.

The capital-heavy model is now the reimbursement target. The figures that look like opportunity — top-ranked beds, high scanner density, world-leading CT use — are exactly what the payer has decided to rein in. Per-capita spending rising faster than the OECD, on a shrinking clinical base, is not sustainable, and MOHW has said as much. The 2026 payment-structure reform cuts the margin on imaging and laboratory tests and redirects money toward physician-intensive essential care. A public "only necessary scans" campaign targets CT overuse directly. For imaging and diagnostics vendors, the installed base is vast but the economics are tightening: tenders shift from premium features toward throughput, uptime and total cost of ownership, and replacement cycles lengthen as hospitals defend margins. The asymmetry inside the numbers is the useful part. CT is over-used and politically exposed; MRI use is below the OECD average and growing fastest, leaving more clinical and commercial headroom.

The pharmaceutical market is large, above average, and increasingly cost-controlled. Per-capita drug sales roughly 47 percent above the OECD average confirm Korea is a serious market, not a marginal one. But the fiscal arithmetic points one way. A separate OECD projection expects the number of new chronic-disease cases in Korea to rise about 58 percent between 2026 and 2050 — the steepest increase in the OECD — and per-capita spending on those diseases to grow around 119 percent. A payer facing that curve, on the current clinician base, will keep tightening. This is the backdrop to the pricing reforms, biomarker-gated coverage and "cover first, verify later" mechanisms already reshaping access. Volume can widen while price is squeezed; plan for both, not one.

There is a caveat worth stating plainly. These are snapshot statistics, and MOHW frames them explicitly as a basis for policymaking. The bed-and-scanner density that looks like a mature market is, in the government's eyes, a distortion to be corrected — through reimbursement cuts, gradual workforce expansion, and a deliberate shift of low-acuity demand out of hospitals and into community and home care, where the long-term-care numbers already show home-based use doubling over the past decade. A vendor that reads the infrastructure density as stable opportunity, rather than as a policy target, is reading only half the page.